Natixis Advisors LLC lowered its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 32.1% during ...

Ionis Pharmaceuticals has entered a licence agreement with Sobi in which the latter obtains exclusive rights to commercialise ...

In return, Ionis will receive an undisclosed upfront payment from Sobi. It is also eligible to receive milestone payments and a tiered royalty on the drug's future sales.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Free Report) has earned an average rating of “Moderate Buy” from the twenty ...

Ionis Pharmaceuticals (IONS) announced that it has entered into a license agreement under which Sobi received exclusive rights in countries ...

We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we ...

Carlsbad’s Ionis Pharmaceuticals struck a deal worth up to $940 million with Japan-based Ono Pharmaceutical for its medicine targeting a chronic blood disorder.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

JPMorgan lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $45 from $47 and keeps a Neutral rating on the shares. The firm ...

Arrowhead Pharmaceuticals, Inc. shines with 19 clinical programs, strategic partnerships, and promising RNAi data. Click for ...

Alnylam Pharmaceuticals, Inc.’s ALNY share price has surged by 11.75%, which has investors questioning if this is right time ...

Ionis and Ultragenyx are competing to develop oligonucleotide treatments for Angelman syndrome, but will Neuren’s peptide ...